设计成熟:第一个同类融合发电厂成熟的挑战
Debbie Kempton1, Chris Waldon1
1United Kingdom Atomic Energy Authority, Culham Campus , Abingdon, Oxfordshire OX14 3DB, UK.
概括
开发用于能源生产的球形托卡马克 (STEP) 原型发电厂 (SPP) 涉及独特的挑战,作为首个同类的聚变能源项目. 整体的工程生命周期方法对于成功交付和商业可行性至关重要.
科学领域:
- 核工程 核工程是指核工程.
- 融合能源研究 融合能源研究
背景情况:
- 大规模的基础设施项目带来了重大挑战.
- 能源生产的球形托卡马克 (STEP) 原型发电厂 (SPP) 是首个同类 (FOAK) 技术演示器.
- 该项目在一个波动,不确定的,复杂和模两可的环境中运作,技术发展迅速.
研究的目的:
- 审查FOAK核聚变发电厂成熟的关键挑战.
- 详细说明 STEP 团队如何成熟能力,并为 SPP 交付做计划.
- 概述一条通往后续核聚变发电厂商业可行性的道路.
主要方法:
- 工程生命周期的整体审查.
- 对能力成熟策略的深入分析.
- 复杂项目的规划方法的检查.
主要成果:
- 确定FOAK核聚变发电厂开发中的关键挑战.
- 阐明 STEP 对能力成熟和设计规划的战略.
- 展示了一种新的方法来规划和成熟复杂的能源基础设施.
结论:
- 整体的工程生命周期视图对于SPP的成功至关重要.
- STEP的方法解决了FOAK核聚变发电厂供应的复杂性.
- 该项目旨在为商业化核聚变能源建立一个可行的途径.
相关概念视频
Nuclear Power
7.7K
Controlled nuclear fission reactions are used to generate electricity. Any nuclear reactor that produces power via the fission of uranium or plutonium by bombardment with neutrons has six components: nuclear fuel consisting of fissionable material, a nuclear moderator, a neutron source, control rods, reactor coolant, and a shield and containment system.
Nuclear Fuels
Nuclear fuel consists of a fissile isotope, such as uranium-235, which must be present in sufficient quantity to provide a...
Nuclear Fuels
Nuclear fuel consists of a fissile isotope, such as uranium-235, which must be present in sufficient quantity to provide a...
7.7K
Nuclear Fusion
18.7K
The process of converting very light nuclei into heavier nuclei is also accompanied by the conversion of mass into large amounts of energy, a process called fusion. The principal source of energy in the sun is a net fusion reaction in which four hydrogen nuclei fuse and ultimately produce one helium nucleus and two positrons.
A helium nucleus has a mass that is 0.7% less than that of four hydrogen nuclei; this lost mass is converted into energy during the fusion. This reaction produces about...
A helium nucleus has a mass that is 0.7% less than that of four hydrogen nuclei; this lost mass is converted into energy during the fusion. This reaction produces about...
18.7K
Introduction to Nuclear Reprogramming
1.9K
Nuclear reprogramming is the process of switching gene expression of one cell type to that of another cell type, usually from a differentiated cell state to an undifferentiated cell state. Differentiation occurs during processes such as development and morphogenesis, tissue regeneration, and malignancy. Cells can also be artificially induced to reprogram their gene expression by techniques such as nuclear transfer, induced pluripotency, and cell fusion. Such techniques have many applications in...
1.9K
Nuclear Fission
9.6K
Many heavier elements with smaller binding energies per nucleon can decompose into more stable elements that have intermediate mass numbers and larger binding energies per nucleon—that is, mass numbers and binding energies per nucleon that are closer to the “peak” of the binding energy graph near 56. Sometimes neutrons are also produced. This decomposition of a large nucleus into smaller pieces is called fission. The breaking is rather random with the formation of a large...
9.6K
Nuclear Transmutation
17.5K
Nuclear transmutation is the conversion of one nuclide into another. It can occur by the radioactive decay of a nucleus, or the reaction of a nucleus with another particle. The first manmade nucleus was produced in Ernest Rutherford’s laboratory in 1919 by a transmutation reaction, the bombardment of one type of nuclei with other nuclei or with neutrons. Rutherford bombarded nitrogen-14 atoms with high-speed α particles from a natural radioactive isotope of radium and observed...
17.5K
Methods of Nuclear Reprogramming
1.8K
Nuclear reprogramming is a process of transforming one cell type into an unrelated cell type by epigenetic changes that alter the cell’s original gene expression pattern. Such epigenetic changes force cells to express a different set of genes, which play a significant role in inducing transformation into other cell types. Nuclear reprogramming offers applications in reproductive cloning for livestock propagation and regenerative medicine — developing patient-specific cells for...
1.8K


